SCHEMBL2260938

SCHEMBL2260938

Cc1cc(C#N)cc(C)c1Oc1ccnc(NC2CCN(c3cc(Cl)cc(C#N)c3)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.44
CYP2C9 P11712 3/20 0.41
PSEN1 P49768 4/20 0.38
PSEN2 P49810 4/20 0.38
APH1B Q8WW43 4/20 0.38
NCSTN Q92542 4/20 0.38
APH1A Q96BI3 4/20 0.38
PSENEN Q9NZ42 4/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
IKBKB O14920 3/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
JAK3 P52333 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
HRH4 Q9H3N8 2/20 0.36
CTSK P43235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263333 0.90 KCNH2 (0.52) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2259038 0.88 KCNH2 (0.42) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2260485 0.84 KCNH2 (0.52) KCNH2CYP2C9CYP2C19CYP3A4IKBKB
SCHEMBL2261778 0.83 KCNH2 (0.41) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2265459 0.83 KCNH2 (0.41) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2262391 0.83 KCNH2 (0.41) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2260086 0.83 KCNH2 (0.51) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2264360 0.82 KCNH2 (0.40) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2260115 0.82 KCNH2 (0.47) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2262209 0.82 KCNH2 (0.48) KCNH2CYP2C9PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CYP2C9 1382/4885PSEN1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.